On Thursday, the Food and Drug Administration issued an emergency use authorization for what it called the world's first breath detection technique.
The InspectIR COVID-19 Breathalyzer is about the size of a carry-on bag, according to the FDA, and can be used in doctor's offices, hospitals, and mobile testing sites. The test, which can yield results in less than three minutes, must be carried out under the supervision of a licensed health care provider.
Dr. Jeff Shuren, head of the Center for Devices and Radiological Health of the United States, has dubbed the device "yet another example of rapid advancement with diagnostic testing for COVID-19."
The FDA claims that the device was 91.2% accurate at identifying positive test samples and 99.3% accurate at identifying negative test samples.
"InspectIR expects to produce approximately 100 instruments per week, which can each be used to evaluate approximately 160 samples per day." "At this level of production, testing capacity using the InspectIR COVID-19 Breathalyzer is expected to increase by approximately 64,000 samples per month."